Does a Minimally Invasive Approach to Liver Resection Improve Postoperative Outcomes?
1 other identifier
observational
9,411
1 country
1
Brief Summary
A retrospective cohort study was conducted using the American College of Surgeons National Surgical Quality Improvement Program (NSQIP) database to identify adult patients who underwent liver resection between 2022 and 2023. Primary outcomes included 30-day mortality, sepsis, septic shock, readmission, and reoperation.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jan 2022
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
December 31, 2023
CompletedFirst Submitted
Initial submission to the registry
September 5, 2025
CompletedFirst Posted
Study publicly available on registry
September 12, 2025
CompletedSeptember 12, 2025
September 1, 2025
2 years
September 5, 2025
September 5, 2025
Conditions
Outcome Measures
Primary Outcomes (5)
30-day mortality
Number of deaths at 30 days
30 days
Number of participants with Sepsis
Number of participants with sepsis at 30 days
30 days
Number of participants with Septic Shock
Number of participants with septic shock at 30 days
30 days
Number of readmissions
Number of participants who had a remission at 30 days
30 days
Number of reoperations
Number of participants who had an reoperation at 30 days
30 days
Study Arms (1)
Participant who underwent liver resection
Adult patients who underwent liver resection between January 2022 and December 2023. Data obtained from the American College of Surgeons National Surgical Quality Improvement Program (NSQIP)
Eligibility Criteria
Participants wit hepatic neoplasms
You may qualify if:
- \- Retrospective patients with condition only
You may not qualify if:
- \- none
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Icahn School of Medicine at Mount Sinai
New York, New York, 10029, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Michael Leitman, MD
Icahn School of Medicine at Mount Sinai
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Dean for Graduate Medical Education and Designated Institutional Official, Professor of Surgery
Study Record Dates
First Submitted
September 5, 2025
First Posted
September 12, 2025
Study Start
January 1, 2022
Primary Completion
December 31, 2023
Study Completion
December 31, 2023
Last Updated
September 12, 2025
Record last verified: 2025-09
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL
- Time Frame
- Immediately following publication. No end date.
- Access Criteria
- Investigators whose proposed use of the data has been approved by an independent review committee ('learned intermediary') identified for this purpose. For individual participant data meta-analysis. Data are available indefinitely at (Link included in the URL field below).
All of the individual participant data collected during the trial, after deidentification.